These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31529318)

  • 21. Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301].
    Wang EQ; Plotka A; Salageanu J; Sattler C; Yunis C
    Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28636184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population PK/PD modeling of low-density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti-PCSK9 monoclonal antibody.
    Wang EQ; Kaila N; Plowchalk D; Gibiansky L; Yunis C; Sweeney K
    CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):2013-2026. PubMed ID: 37994400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.
    Milionis H; Barkas F; Ntaios G; Papavasileiou V; Vemmos K; Michel P; Elisaf M
    Eur J Intern Med; 2016 Oct; 34():54-57. PubMed ID: 27363304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternative Treatment Regimens With the PCSK9 Inhibitors Alirocumab and Evolocumab: A Pharmacokinetic and Pharmacodynamic Modeling Approach.
    Scherer N; Dings C; Böhm M; Laufs U; Lehr T
    J Clin Pharmacol; 2017 Jul; 57(7):846-854. PubMed ID: 28263403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging biologic therapies for hypercholesterolaemia.
    Pucci G; Cicero AF; Borghi C; Schillaci G
    Expert Opin Biol Ther; 2017 Sep; 17(9):1077-1087. PubMed ID: 28617192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.
    Zhang XL; Zhu QQ; Zhu L; Chen JZ; Chen QH; Li GN; Xie J; Kang LN; Xu B
    BMC Med; 2015 Jun; 13():123. PubMed ID: 26099511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials.
    Geng Q; Li X; Sun Q; Wang Z
    Cardiol J; 2022; 29(4):574-581. PubMed ID: 34581425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of monoclonal antibodies against PCSK9 on clinical cardiovascular events : A meta-analysis of randomized controlled trials.
    Zhu Y; Shen X; Jiang Q; Wang Z; Wang Z; Dong X; Li J; Han Q; Zhao J; Wang B; Liu L
    Herz; 2019 Jun; 44(4):336-346. PubMed ID: 29116337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia.
    Sible AM; Nawarskas JJ; Anderson JR
    Cardiol Rev; 2016; 24(3):141-52. PubMed ID: 26886466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia.
    Verbeek R; Stoekenbroek RM; Hovingh GK
    Eur J Pharmacol; 2015 Sep; 763(Pt A):38-47. PubMed ID: 25989132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PCSK9 inhibition in patients with hypercholesterolemia.
    Desai NR; Sabatine MS
    Trends Cardiovasc Med; 2015 Oct; 25(7):567-74. PubMed ID: 25771732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PCSK9 inhibitors: an overview on a new promising lipid-lowering therapy.
    Denegri A; Petrova-Slater I; Pasotti E; Rossi MG; Pedrazzini GB; Moccetti T; Moccetti M
    J Cardiovasc Med (Hagerstown); 2016 Apr; 17(4):237-44. PubMed ID: 26855411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.
    White CM
    Ann Pharmacother; 2015 Dec; 49(12):1327-35. PubMed ID: 26424774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of PCSK9 monoclonal antibodies.
    Iqbal Z; Dhage S; Mohamad JB; Abdel-Razik A; Donn R; Malik R; Ho JH; Liu Y; Adam S; Isa B; Stefanutti C; Soran H
    Expert Opin Drug Saf; 2019 Dec; 18(12):1191-1201. PubMed ID: 31623472
    [No Abstract]   [Full Text] [Related]  

  • 37. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
    Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
    JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evolocumab (Repatha®) : a human monoclonal antibody against PCSK9 protein as potent cholesterol-lowering therapy].
    Wallemacq C
    Rev Med Liege; 2017 Nov; 72(11):505-512. PubMed ID: 29171950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.
    Schreml J; Gouni-Berthold I
    Curr Med Chem; 2018; 25(13):1538-1548. PubMed ID: 28618994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1.
    Chasman DI; Hyde CL; Giulianini F; Danning RD; Wang EQ; Hickling T; Ridker PM; Loomis AK
    Sci Rep; 2022 Mar; 12(1):4266. PubMed ID: 35277540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.